ArticleMedComm2026
Phenotypes and Clinical Outcome of Heart Failure With Preserved Ejection Fraction Patients in China: Findings From the Chinese Cardiovascular Association Database-Heart Failure Center Registry.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Macrophage-Dependent Intercellular Crosstalk in Multiphenotypic Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2026Review
- Influence of Phenotypes on Short-Term Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction-Insights from a North-Eastern Romanian Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Efficacy and safety of quadruple therapy versus triple therapy in patients with heart failure with preserved ejection fraction: a propensity score-matched real-world study.Frontiers in cardiovascular medicine · 2026Article
- Risk prediction for long-term cardiovascular events in patients with concurrent hypertension, HFpEF, and unstable angina: a multicenter machine learning-assisted cohort study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous syndrome that poses challenges for therapeutic development and contributes to suboptimal patient outcomes. The phenotypic classification of patients with HFpEF to guide etiology-specific therapeutic strategies represents a rational approach to address the current dilemma. However, the clinical outcomes of HFpEF under different etiological classifications remain poorly understood. Here, we assessed the clinical outcomes of HFpEF patients across different etiological phenotypes, based on a novel classification system comprising five categories: vascular-related, cardiomyopathy-related, right heart/pulmonary-related, valvular/rhythm-related, and extracardiac disease-related HFpEF. Data from the Chinese Cardiovascular Association Database-Heart Failure Center Registry (2017-2021) were analyzed, including 51,466 hospitalized HFpEF patients with 1-year follow-up. Significant differences in baseline characteristics and clinical outcomes were observed among phenotypes. Patients with right heart/pulmonary-related, valvular/rhythm-related, and extracardiac disease-related HFpEF showed a higher incidence of adverse outcomes. Specifically, the right heart/pulmonary-related and valvular/rhythm-related phenotypes were associated with increased heart failure rehospitalization, while extracardiac disease-related HFpEF was linked to higher cardiovascular mortality. Prognostic risk factors also varied across phenotypes. In conclusion, 1-year outcomes exhibit significant variations across HFpEF phenotypic subgroups. Future studies should explore whether phenotype-specific personalized treatment strategies can improve clinical outcomes, especially in high-risk phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.